On July 23, 2026, the FDA Pharmacy Compounding Advisory Committee will formally evaluate BPC-157 for inclusion on the 503A bulks list. The April 23 reclassification removed BPC-157 from the Category 2 restricted list — restoring legal compounding through licensed 503A pharmacies in the interim — but the durable shelf status is what the July meeting will decide. Public comments closed July 9. This is what the dossier in front of the committee actually contains, and how Limitless prescribes BPC-157 inside the uncertainty that remains.
What BPC-157 is.
BPC-157 (Body Protection Compound-157) is a 15-amino-acid synthetic peptide derived from a sequence found in human gastric juice. The name is descriptive: animal models consistently show accelerated repair of gastric and intestinal mucosa, tendon, ligament, and skeletal muscle after BPC-157 exposure. The proposed mechanisms span nitric oxide synthesis, VEGF expression and angiogenesis, modulation of the dopaminergic and serotonergic systems, and effects on growth-factor signaling pathways — none of which are individually proven definitive in human tissue, but which collectively form a plausible therapeutic story.
The animal record is unusually consistent.
This is the part of the dossier that matters most for the regulatory case. Across hundreds of preclinical studies — multiple species, multiple injury models — BPC-157 demonstrates accelerated healing with a remarkable safety profile. There is no clean signal of organ toxicity, no dose-dependent adverse-event curve that has been replicated, and the molecule has been studied for over two decades. For a compound being evaluated for inclusion on a compounding bulks list rather than for an NDA, this kind of consistent preclinical record is exactly the type of evidence the committee weighs.
The human record is thin but improving.
The published human data is small in volume — early Phase II work in inflammatory bowel disease (ulcerative colitis) and a handful of orthopedic case series. The therapeutic indication the FDA highlighted in the briefing materials is ulcerative colitis, which is the specific indication that anchors the regulatory case. Outside of those formal trials, BPC-157 has been used extensively off-label by sports medicine, regenerative medicine, and gastroenterology clinics for at least a decade. The collective real-world experience is substantial; the published data still trails it.
What the credible uncertainty looks like.
Honestly: long-term human safety data above 12 months is not robust. Cancer signal is theoretically plausible because of pro-angiogenic and growth-factor effects, though no clinical signal has emerged. Pharmacokinetics in humans are incompletely characterized, especially for the oral route some clinics promote. The Limitless position is that the subcutaneous and intramuscular routes are better-characterized and that we do not currently use oral preparations.
How we prescribe inside that uncertainty.
BPC-157 is on the Limitless menu for indicated patients — typically tendinopathy, joint injury with stalled rehabilitation, post-surgical recovery, or inflammatory gut conditions where conventional therapy has plateaued — and we pair it with TB-500 in most musculoskeletal cases. Standard dosing is 250–500 mcg subcutaneously daily for 4–8 weeks, with reassessment. We do not prescribe it for active or recent malignancy, in pregnancy, or as a generic "feel-better" peptide. We disclose the regulatory situation honestly: legally compoundable through licensed 503A pharmacies right now, with the durable status pending the July PCAC outcome.
What to watch on July 23.
The committee vote is the headline. Equally important are the conditions any favorable recommendation might attach — labeling restrictions, indication-specific limits, route-of-administration constraints, or batch-testing requirements. We will publish a recap on this site within 48 hours of the committee's decision and update the protocol page if the operational picture changes.